Rare Anaemias, Sickle-Cell Disease and COVID-19
- PMID: 32420949
- PMCID: PMC7569637
- DOI: 10.23750/abm.v91i2.9532
Rare Anaemias, Sickle-Cell Disease and COVID-19
Abstract
For rare haematological diseases (RHD), the first question to be answered is if patients with be- nign red blood cell (RBC) defects like haemoglobinopathies, membranopathies and enzymopathies are more vulnerable to COVID-19 infection. Up to now, there is no yet literature on the subject, but, like in general population, the presence of comorbidities such as diabetes, heart disease, pulmonary hypertension, reduced kidney and/or liver function, worsen the effects of the infection. Splenectomy may be an additional risk factor.
Conflict of interest statement
Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article
References
-
- World Health Organisation (WHO) https://www.who.int/emergencies/diseases/novel-coronavirus-2019 .
-
- European Commission. Health and Food Safety Directorate General. “COVID.19 Clinical Management Support System”. e-News. 27/03/2020. https://www.vml.org/enewsmarch-27-2020/
-
- COVID-19 and Rare Diseases. Orphanews 27 of March. 2020. https://www.drroyspencer.com/2020/03/covid-19-deaths-in-europe-excess-mo...
-
- COVID-19 and Rare Hematological Diseases. EuroBloodNet. https://eurobloodnet.eu/covid-19/
-
- Thalassemia International Federation. The COVID–19 pandemic and haemoglobin disorders. A contribution of Thalassaemia International Federation to its global patients’ community. https://thalassaemia.org.cy/publications/tif-publications/a-tif-proposed... .
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
